Brief: Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To LSTA1 For The Treatment Of Malignant Glioma
08/08/2023 14:03
Aug 8 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG
DESIGNATION
GRANTED TO LSTA1 FOR THE TREATMENT OF MALIGNANT GLIOMA
* LISATA THERAPEUTICS INC - EXPECTS THAT FIRST PATIENT WILL
BE
TREATED IN Q4 OF 2023
Source text for Eikon: ID:nGNX13Zn6M
Further company coverage: LSTA.O
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal